ArticleBlood advances2023

Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies.

Andres Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.